Health and Fitness Health and Fitness
Tue, June 8, 2010
[ 01:41 PM ] - Market Wire
Community Health Systems to Participate in Goldman Sachs 31st Annual Global Healthcare Conference
[ 01:41 PM ] - Market Wire
Forest Laboratories und TransTech Pharma schlieen .. cklung und Kommerzialisierung von Glucokinase-Akt
[ 01:41 PM ] - Market Wire
LifePoint Hospitals to Participate in Goldman Sachs 31st Annual Global Healthcare Conference
[ 01:30 PM ] - Market Wire
Molecular Insight Pharmaceuticals Presents Oncolo .. t Society of Nuclear Medicine 2010 Annual Meeting
[ 01:21 PM ] - Market Wire
Elan to Present at the Goldman Sachs 31st Annual Healthcare Conference
[ 12:26 PM ] - Market Wire
Paradigm to Become Current With Financial Disclos .. porting and Update on Retimax(TM) FDA Application
[ 11:12 AM ] - Market Wire
Assisted Living Concepts, Inc. to Attend CJS Securities Conference
[ 09:55 AM ] - Market Wire
Neostem Set to Become First Fully Commercial Stem Cell Medicine Play
[ 07:50 AM ] - Market Wire
MMR Information Systems, Inc. Retains The Michael .. dentify Strategic Alliances and M&A Opportunities
[ 06:00 AM ] - Market Wire
O.C. Beverages Products Arrive
[ 06:00 AM ] - Market Wire
High Desert Gold Announces the Start of Drilling at the Gold Springs Project
[ 05:30 AM ] - Market Wire
Aoxing Pharmaceutical Company Announces Completion of $8.05 Million Bank Loan Financing
[ 05:19 AM ] - Market Wire
Biomerica Purchases Patented Technology and Manuf .. T Test to Indentify Individuals at Risk of Develo
[ 05:00 AM ] - Market Wire
Spencer Pharmaceutical Inc. Announces Securities Awareness Campaign
[ 05:00 AM ] - Market Wire
Omni Bio Announces FDA IND Clearance for Alpha-1 Antitrypsin (AAT) Type 1 Diabetes Clinical Trial
[ 04:30 AM ] - Market Wire
CytoSorbents Corporation to Present at the In3 East Medical Device Conference
[ 04:00 AM ] - Market Wire
Auxilium Pharmaceuticals Announces Two Year Recur .. Rate of 19.3% for Joints Treated With XIAFLEX(R)
Mon, June 7, 2010
[ 11:00 PM ] - Market Wire
Astellas Announces Successful Completion of Tender Offer for Shares of OSI
[ 07:08 PM ] - Market Wire
IntegraMed® to Open 10 New Vein Clinics Across Seven States
[ 02:41 PM ] - Market Wire
Universal American Corp. to Present at the Goldma .. obal Healthcare Conference on Thursday, June 17th
[ 12:00 PM ] - Market Wire
Sunesis Announces Data From Phase 2 Clinical Prog .. loid Leukemia Support Phase 3 Trial in Relapsed o
[ 09:50 AM ] - Market Wire
Exceptional Survival Data, Lower Costs Key to the .. ax(R) - Northwest Biotherapeutics' Vaccine for Mu
[ 06:45 AM ] - Market Wire
AVI BioPharma Discloses New Contract With U.S. Go .. on to Advance Development of AVI-7100 as H1N1 Flu
[ 06:00 AM ] - Market Wire
Signature Eyewear Reports Second Quarter Earnings; 18th Consecutive Profitable Quarter
[ 06:00 AM ] - Market Wire
Provista Life Sciences Initiates Validation Study .. Onko-Sure(TM) IVD Cancer Test as a General Cance
[ 05:35 AM ] - Market Wire
Aeterna Zentaris Announces Phase 1 Data of Single .. tment of Recurrent Pediatric Solid Tumors, Includ
[ 05:30 AM ] - Market Wire
Aoxing Pharmaceutical Company to Present at Jeffe .. Global Life Sciences Conference in New York City
[ 05:30 AM ] - Market Wire
AspenBio Pharma Updates on AppyScore(TM) FDA 510(k) Filing and Data Analysis
[ 05:00 AM ] - Market Wire
MDS to Release Second Quarter 2010 Financial Results
[ 04:30 AM ] - Market Wire
Aeterna Zentaris Presents Positive Efficacy and S .. ta for AEZS-108 in Ovarian Cancer at ASCO Meeting

Aeterna Zentaris Presents Positive Efficacy and Safety Data for AEZS-108 in Ovarian Cancer at ASCO Meeting


Published on 2010-06-07 04:40:43 - Market Wire
  Print publication without navigation


 Conclusion - AEZS-108 was active and well tolerated in patients with heavily pre-treated platinum and taxane resistant ovarian cancer; - The safety profile confirmed the dose of 267 mg/m2; - Hematological toxicity was rapidly reversible; - Non-hematological toxicities were usually limited to lower severity; - Tolerability and CBR compare favourably with topotecan and liposomal doxorubicin; - Overall survival is encouraging as all patients treated with AEZS-108 were platinum-resistant.
Contributing Sources